2023 ASCO中國之聲 | 頭頸部腫瘤壁報部分中國研究匯總！

標題：Prognostic value of circulating Epstein-Barr virus DNA level post-induction chemotherapy for patients with nasopharyngeal carcinoma: A recursive partitioning risk stratification analysis.

報告人: 孔芳芳

單位：復旦大學附屬腫瘤醫院

標題：A phase Ib/II study of GFH018 in combination with toripalimab in recurrent/metastatic nasopharyngeal carcinoma (R/M NPC).

報告人：麥海強

單位：中山大學腫瘤防治中心

標題：Influence of widely targeted quantitative lipidomics on plasma lipid predictors and pathway dysregulation for nasopharyngeal carcinoma.

報告人：陳曦

單位：中山大學腫瘤防治中心

標題：Efficacy and safety of sintilimab plus bevacizumab in metastatic nasopharyngeal carcinoma after failure of platinum-based chemotherapy: An open-label phase II study.

報告人：Nian Lu

單位：中山大學腫瘤防治中心

標題：Results from two phase II studies of SI-B001, an EGFR×HER3 bispecific antibody, with/without chemotherapy in patients (pts) with recurrent and metastatic head and neck squamous cell carcinoma (HNSCC).

報告人：薛麗瓊

單位：同濟大學附屬東方醫院

標題：TCR-T cells armored with immune checkpoint blockade in EBV-positive nasopharyngeal carcinoma: The first-in-human phase 1/2 trial.

報告人：Ling Peng

單位：廣東天科雅生物醫藥科技有限公司

標題：Low-dose fractionated radiotherapy combined with neoadjuvant chemotherapy for T3-4 nasopharyngeal carcinoma patients: Preliminary results of a phase II randomized controlled trial.

報告人：馮梅

單位：四川省腫瘤醫院

標題：Radiotherapy alone versus concurrent or adjuvant chemoradiotherapy for nasopharyngeal carcinoma patients with negative Epstein-Barr virus DNA post-induction chemotherapy.

報告人：孔芳芳

單位：復旦大學附屬腫瘤醫院

標題：Induction chemotherapy with nedaplatin, docetaxel and 5-fluorouracil followed by concurrent nedaplatin and radiotherapy in locoregionally advanced nasopharyngeal carcinoma: A single arm, open label, phase II clinical trial.

報告人：Chen Fangzheng

單位：廣州醫科大學附屬腫瘤醫院

標題：Induction chemotherapy and toripalimab for larynx preservation in resectable locally advanced laryngeal/hypopharyngeal carcinoma: Preliminary results of INSIGHT study.

報告人：區曉敏

單位：復旦大學附屬腫瘤醫院

標題：A pilot phase II trial of neoadjuvant camrelizumab plus nab-paclitaxel and cisplatin (NeoCPC) for locoregionally advanced, resectable squamous cell carcinoma of the head and neck.

報告人：Di Wu

單位：中山大學腫瘤防治中心

標題：Induction therapy of toripalimab combined with docetaxel and cisplatin in locally advanced hypopharyngeal squamous cell carcinoma (HPSCC): A single-arm, phase II clinical trial.

報告人：白春梅

單位：北京協和醫院

標題：Nab-paclitaxel plus cisplatin versus docetaxel plus cisplatin and 5-FU induction chemotherapy followed by concurrent chemoradiotherapy in locally advanced nasopharyngeal carcinoma: A multicenter parallel controlled phase III trial.

報告人：呂星

單位：中山大學腫瘤防治中心

標題：Prospective study of integrating post-radiotherapy [18F] fluorodeoxyglucose-positron emission tomography/computed tomography scan and plasma Epstein-Barr virus DNA in surveillance of locoregionally advanced nasopharyngeal carcinoma.

報告人：唐林泉

單位：中山大學腫瘤防治中心

標題：Neoadjuvant chemoimmunotherapy for the treatment of locally advanced laryngeal and hypopharyngeal squamous cell carcinoma: A single-arm phase 2 clinical trial.

報告人：陳艷峰

單位：中山大學腫瘤防治中心

標題：Neoadjuvant low-dose radiotherapy, tislelizumab, combined with albumin-bound paclitaxel and cisplatin in resectable locally advanced head and neck squamous cell carcinoma (NeoRTPC02): The first-stage result from an open label, single-arm, two stage, phase II clinical trial.

報告人：劉志剛

單位：南方醫科大學附屬東莞醫院腫瘤中心

標題：Neoadjuvant tislelizumab combined with APF for patients with locally advanced head and neck squamous cell carcinoma: A prospective single-arm clinical trial.

報告人：閆婧

單位：南京大學醫學院附屬鼓樓醫院

標題：Tislelizumab plus chemotherapy as induction treatment followed by chemoradiotherapy or surgery in locally advanced hypopharyngeal squamous cell carcinoma: A single-arm, phase II trial.

報告人：桂琳

單位：中國醫學科學院附屬腫瘤醫院

標題：A multicenter, single-arm phase 2 study of surufatinib plus toripalimab for patients with locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer.

報告人：季冬梅

單位：復旦大學附屬腫瘤醫院

標題：Response-adapted therapy for locally advanced nasopharyngeal carcinoma based on clinical response and circulating Epstein-Barr virus DNA level post induction chemotherapy.

報告人：胡超蘇

單位：復旦大學附屬腫瘤醫院